Abstract: 【Abstract】 Mycophenolate mofetil can selectively inhibit the proliferation and activity of T and B lymphocytes, and has been widely used in the treatment of a variety of immune-related skin diseases. On the basis of Chinese and international literature, a proposal was formed after discussion among multiple experts from different regions in China. According to the criteria for grading the strength of recommendations established by the Oxford Centre for Evidence-based Medicine, the strength of recommendation is grade A for use of mycophenolate mofetil in the treatment of moderate to severe adult plaque psoriasis vulgaris, adult bullous pemphigoid and pemphigus vulgaris, grade B for use of mycophenolate mofetil in the treatment of adult systemic sclerosis, moderate to severe adult eczema and moderate to severe atopic dermatitis, and grade C for use of mycophenolate mofetil in the treatment of cutaneous lupus erythematosus, dermatomyositis, amyopathic dermatomyositis, childhood systemic sclerosis, childhood bullous pemphigoid and childhood pemphigus, moderate to severe childhood eczema and atopic dermatitis.

Key words: Autoimmune diseases, Psoriasis, Pemphigoid, bullous, Pemphigus, Scleroderma, systemic, Dermatitis, Dermatomyositis, Mycophenolate mofetil